Drugs / Letetresgene autoleucel
Letetresgene autoleucel
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03168438 | Aug 2017 → Jul 2020 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02588612 | Feb 2016 → Aug 2020 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03967223 | Dec 2019 → Mar 2024 overdue | neoplasm | USWM CT, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05993299 | Dec 2019 → Oct 2022 overdue | neoplasm | USWM, LLC (dba US WorldMeds) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06703346 | Dec 2019 → Mar 2024 overdue | neoplasm | USWM CT, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03697824 | Feb 2019 → Jul 2022 | neoplasm | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT02992743 | Dec 2016 → Nov 2021 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-01 | GlaxoSmithKline | Results GSK to showcase scientific advances and progress in oncology at ASCO and EHA gsk.com ↗
A presentation of note will include findings from an interim analysis on the safety and efficacy of lete-cel in myxoid/round cell liposarcoma (ASCO abstract #11521). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-01 | GlaxoSmithKline | GSK to showcase scientific advances and progress in oncology at ASCO and EHA gsk.com ↗ |
| 2017-09-07 | GlaxoSmithKline | GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794) gsk.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Letetresgene autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03168438 ↗ |
| Known as | GSK3377794 | “This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794), a genetically modified autologous T-cell therapy targeting New York...” PMID 36534160 ↗ Apr 20235“Letetresgene autoleucel (GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor engineered TCR T-cells.” NCT02588612 ↗ “Letetresgene autoleucel (Lete-Cel (GSK3377794))” NCT06703346 ↗ “Letetresgene autoleucel (lete-cel, GSK3377794)” NCT03967223 ↗ “letetresgene autoleucel (GSK3377794)” NCT02992743 ↗ |
| Known as | lete-cel | “This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794), a genetically modified autologous T-cell therapy targeting New York...” PMID 36534160 ↗ Apr 20233“In this pilot study, we assessed the adoptive T-cell therapy NY-ESO-1c259T letetresgene autoleucel (lete-cel) in patients with human leukocyte antigen (HLA)-A*02:01-,...” PMID 39836945 ↗ Jan 2025 “Letetresgene autoleucel (Lete-Cel (GSK3377794))” NCT06703346 ↗ “Letetresgene autoleucel (lete-cel, GSK3377794)” NCT03967223 ↗ |
| Modality | Cell therapy | “T-cell receptor engineered TCR T-cells” NCT02588612 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT02588612 ↗ |